Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. [electronic resource]
Producer: 20141203Description: 3242-8 p. digitalISSN:- 1527-7755
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Calcifediol -- blood
- Cyclophosphamide -- administration & dosage
- Doxorubicin -- administration & dosage
- Female
- Humans
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Middle Aged
- Prednisone -- administration & dosage
- Risk Factors
- Rituximab
- Treatment Outcome
- Vincristine -- administration & dosage
- Vitamin D Deficiency -- complications
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.